New Cannabis Ventures reports the new cannabis defacto corporate speak.
We’re also surprised to see how little if any reaction there’s been about a cannabis company working closely with a company entrenched in opiates. Being a little cynical we’ll watch to see how that develops.
We’re diversifying our production capabilities on the continent in anticipation of rapid European market expansion. In addition to a large licenced production footprint in Odense, Denmark we are working closely with our partner Alcaliber to capture market share by scaling supply.
Meanwhile over at Canada’s Globe & Mail they report on developments at
Marijuana producer Tilray….. partners with pharmaceutical firm Sandoz
As part of the agreement announced Monday, Tilray will become the exclusive collaborator with Sandoz Canada on cannabis-based medical products which are non-smokable or non-combustible such as gel caps and sprays for the domestic market.
Subject to future regulatory changes, the aim is to distribute on a wholesale level these co-branded products to Canadian hospitals and pharmacies, said Tilray’s chief executive officer Brendan Kennedy.
There is still much skepticism towards the medical marijuana industry, and this collaboration with a recognized pharmaceutical company will help alleviate that, he said.